Navigation Links
Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Date:1/25/2010

Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm

QUÉBEC CITY, Jan. 25 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that its partner, Keryx Biopharmaceuticals ( KERX), presented updated results yesterday on the clinical activity of perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor for cancer, in combination with capecitabine (Xeloda(R)) as a treatment for advanced, metastatic colon cancer. Abstract #447, entitled, "Randomized Phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colon cancer (mCRC): Updated results", was presented yesterday in a poster during the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held in Orlando, Florida. Keryx is Æterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok in South Korea while Æterna Zentaris retains rights for the rest of the world.

Study Design

In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, heavily pre-treated patients with second- or third-line metastatic colon cancer were randomized to receive cape
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
2. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
4. AEterna Zentaris Announces Appointment of New Board Member
5. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
8. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
9. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
10. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
11. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 Today the National ... of grants for the Brain Research through Advancing ... to develop and revolutionize new methods of understanding ... human brain. This first round of grants totaling ... was allocated to more than 100 investigators in ...
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:9/30/2014)... 30, 2014 Applying a well-known optical phenomenon ... Harvard University has demonstrated the ability to "paint" ... that holds promise for making future, flexible electronic ... sides of next-gen rocket ships and spacecraft with ... through oil in water, it becomes iridescent, revealing ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 long-travel ... for measuring displacement in rubber and other soft ... distance, the DSES-1000 can measure elongations up to ... mm. In addition, it achieves +/- 0.2 percent ... +/- 100 µm below 50-mm stroke. , The ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2
... the pro and cons of radio frequency identification technology ... at the second annual Wisconsin RFID Conference. Sponsored by ... at the steps for implementing RFID and predicted where ... about a product in an electronic tag. The tags ...
... MILWAUKEE - Metavante Corporation , a supplier of ... Corporation , has acquired two financial firms located in Virginia ... purchased GHR Systems , a provider of loan origination ... million and the deal is expected to close in the ...
... Wis. - It would be misleading to suggest that ... human embryos. They arent. In fact, no scientist in the ... ,It would also be disingenuous to suggest the process for ... at the outset -- from the process used in ...
Cached Biology Technology:Conference studies applications and lessons of RFID 2Conference studies applications and lessons of RFID 3The Attack of the Clones: No, its not a summer movie 2The Attack of the Clones: No, its not a summer movie 3
(Date:10/1/2014)... Reserve University researchers hope to take a healthy salad ... aggressive form of breast cancer in leafy greens. , ... the vaccine either by eating the salad or making ... assistant professor of biomedical engineering at Case Western Reserve ... The Susan G. Komen breast cancer organization is funding ...
(Date:10/1/2014)... 2014 Novel detection technology ... field  The life science field has ... the years. Some are shooting stars and others ... novel detection technology that has raised much enthusiasm ... technology is becoming commercially available. With their unique ...
(Date:9/30/2014)... visit the Mediterranean each year, but its deep-blue ... Earth. Almost 1,000 alien species, including fish, crustaceans, ... through human activities. In the open-access journal ... of researchers analyzed data from a new information ... how the introduction of alien species has changed ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3First-of-a-kind Solution for Utilizing Photon Upconversion 2Biodiversity in the Mediterranean is threatened by alien species 2
... bacteria that break down pollutants do their job and ... toxic wastes. , Bacteria called Dehalococcoides ethenogenes, discovered in ... professor of civil and environmental engineering, and isolated and ... now in wide use to detoxify such carcinogenic chemicals ...
... announced the publication in the June 23 issue of the ... gene therapy trial for Parkinson’s disease and the first report ... for any adult neurodegenerative disease. , The open label ... disease demonstrated both a lack of adverse events related to ...
... in the United States and other northern mid- ... in offsetting global warming than previously thought, according ... The study, which sheds light on the so-called ... are removing an unexpectedly high proportion of carbon ...
Cached Biology News:Helping chlorine-eating bacteria clean up toxic waste 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 3Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 4Scientists close in on missing carbon sink 2Scientists close in on missing carbon sink 3
... plus assay system offers the ... Designed for batch-processing systems, Long ... density microplates such as 384-well ... Convenient storage conditions ( 2 ...
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... steadylite plus assay system offers ... sensitivity, Designed for batch-processing systems, ... higher density microplates such as ... free, Convenient storage conditions ( ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Biology Products: